Codexis, Inc. (CDXS): Price and Financial Metrics


Codexis, Inc. (CDXS): $23.88

-0.02 (-0.08%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CDXS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 491

in industry

CDXS Stock Summary

  • CDXS's price/sales ratio is 22.29; that's higher than the P/S ratio of 90.46% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.43 for Codexis Inc; that's greater than it is for merely 21.14% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Codexis Inc is reporting a growth rate of 98.62%; that's higher than 87.36% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Codexis Inc are MYOV, BCYC, SILC, KPTI, and BLDP.
  • Visit CDXS's SEC page to see the company's official filings. To visit the company's web site, go to www.codexis.com.

CDXS Stock Price Chart Interactive Chart >

Price chart for CDXS

CDXS Price/Volume Stats

Current price $23.88 52-week high $29.56
Prev. close $23.90 52-week low $10.28
Day low $23.76 Volume 380,900
Day high $24.70 Avg. volume 682,922
50-day MA $22.88 Dividend yield N/A
200-day MA $17.95 Market Cap 1.54B

Codexis, Inc. (CDXS) Company Bio


Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.


CDXS Latest News Stream


Event/Time News Detail
Loading, please wait...

CDXS Latest Social Stream


Loading social stream, please wait...

View Full CDXS Social Stream

Latest CDXS News From Around the Web

Below are the latest news stories about Codexis Inc that investors may wish to consider to help them evaluate CDXS as an investment opportunity.

Codexis (NASDAQ:CDXS) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | March 30, 2021

TSMC, BYD, Komatsu, Surface Oncology And 3D Systems — What Cathie Wood's Ark Bought And Sold Today

Every night, Cathie Wood’s Ark Investment Management sends out an email listing the stocks that were bought or sold by the firm's ETFs that day. In recent months, the emails have been known to cause certain stocks to see a spike in the after-hours session. Here’s a list of what the hedge fund bought or sold on Tuesday. 3D Systems Corp (NYSE: DDD ): Bought 558,900 shares of the printing engineering company, representing about 0.46% of the ETF. 3D shares closed 9.62% lower at $26.22 on Tuesday and rose 1.07% in the after-hours. It has a 52-week high of $56.5 and low of $4.60. Accolade Inc (NASDAQ: ACCD ): Bought 38,112 shares of the personalized health-tech company, representing about 0.016% of the company. Accolade shares closed 2.2% lower at $42.03 on Tuesday and were further down 1.26%...

Benzinga | March 23, 2021

Global Proteinase K Market Analysis Report 2020-2027 Featuring Key players - Merck, BBI Solutions, Codexis, SBS Genetech, Hoffmann-La Roche, Amicogen Amano Enzyme & Advanced Enzymes Technologies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area; By Form, By Regions; Segment Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering. The global proteinase K market size is predicted to reach US$ 107.5 Million by 2027 The report "Proteinase K Market Share, Size, Trends, Industry Analysis Report, By Therapeutic Area (Infectious diseases, Diabetes, Oncology, Cardiology, Nephrology, Autoimmune diseases, N

Business Wire | March 1, 2021

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2021

Upgrades Loop Capital upgraded the previous rating for Albemarle Corp (NYSE:ALB) from Hold to Buy. In the fourth quarter, Albemarle showed an EPS of $1.17, compared to $1.73 from the year-ago quarter. At the moment, the stock has a 52-week-high of $188.35 and a 52-week-low of $48.89. Albemarle closed at $157.34 at the end of the last trading period. According to Barclays, the prior rating for ManpowerGroup Inc (NYSE:MAN) was changed from Underweight to Overweight. ManpowerGroup earned $1.48 in the fourth quarter, compared to $2.33 in the year-ago quarter. At the moment, the stock has a 52-week-high of $99.36 and a 52-week-low of $49.57. ManpowerGroup closed at $94.41 at the end of the last trading period. For Life Storage Inc (NYSE:LSI), Evercore ISI Group upgraded the previous rating o...

Yahoo | March 1, 2021

Phenylketonuria Treatment Market Analysis Released in Latest Industry Report 2020: BioMarin, Codexis, Erytech Pharma, SOM Innovation Biotech, Retrophin

Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. The report aims to provide an overview of Phenylketonuria Treatment market with detailed

OpenPR | February 26, 2021

Read More 'CDXS' Stories Here

CDXS Price Returns

1-mo 17.58%
3-mo -8.01%
6-mo 65.66%
1-year 112.46%
3-year 104.10%
5-year 588.18%
YTD 9.39%
2020 36.52%
2019 -4.25%
2018 100.00%
2017 81.52%
2016 8.75%

Continue Researching CDXS

Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:

Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch

Page generated in 1.0085 seconds.